<DOC>
	<DOC>NCT02806505</DOC>
	<brief_summary>This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.</brief_summary>
	<brief_title>HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Serum hepatitis C virus ribonucleic acid (HCV RNA) quantifiable at greater than (&gt;) 600 IU/mL Liver biopsy consistent with chronic hepatitis C infection obtained within 2 years of enrollment Compensated liver disease without cirrhosis Participants with endstage renal disease undergoing hemodialysis Negative serum pregnancy test (for women of childbearing potential) documented within the 24hour period prior to the first dose of study drug All fertile participants must have been using effective contraception during treatment with study drug Interferon therapy at any previous time Liver cirrhosis Signs and symptoms of hepatocellular carcinoma History or other evidence of decompensated liver disease Any investigational drug less than or equal to 6 weeks prior to the first dose of study drug History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures) Poorly controlled diabetes Thyroid dysfunction not adequately controlled Evidence of severe retinopathy or clinically relevant ophthalmological disorder Severe hyperparathyroidism defined as intact Parathyroid Hormone (PTH) &gt; 800 picogram/milliliter (pg/mL) Therapy with any systemic antiviral, antineoplastic or immunomodulatory treatment â‰¤ 6 months prior to the first dose of study drug Acute renal failure Women with ongoing pregnancy or breast feeding Positive test at screening for antiHAV IgM Ab (hepatitis A virus immunoglobulin M antibody), hepatitis B surface antigen (HBsAg), antiHBc (hepatitis B core) IgM Ab, antiHIV (human immunodeficiency virus) Ab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>